MEDIDATA-PAREXEL EXTENDED PARTNERSHIP TO ENHANCE DECENTRALISED CLINICAL TRIAL DELIVERY

KUALA LUMPUR, Feb 7 -- Medidata, a Dassault Systèmes company, announced that Parexel, a leading global clinical research organisation (CRO) focused on development and delivery of innovative new therapies to advance patient health, is extending their 15-year global strategic partnership.

This builds upon the trusted relationship between the two companies and sets the goal of jointly pioneering a new era of decentralised clinical trial technology (DCT) for the life sciences industry, according to a statement.

“The COVID-19 pandemic showed us that we can leverage DCT technologies to expedite and enhance the entire clinical trials process,” said Patient Cloud Chief Executive Officer at Medidata, Anthony Costello.

“The relationship with Parexel represents an enormous opportunity to forever redefine the patient experience and development timelines for the development of new medicines and vaccines.”

Meanwhile, Chief Patient Officer at Parexel, Clare Grace, Ph.D. said: “Medidata’s DCT technologies further support our efforts in a market where nearly 75 per cent of proposals include at least a hybrid trial model. We’re pleased to partner with them as we continue to expand our offerings in this area.”

Parexel also participates in Medidata’s Early Adopter DCT programme leveraging its unified platform, the myMedidata patient portal, Sensor Cloud, and Medidata’s proprietary Patient Centricity by Design programme.

Parexel provides feedback and insights to help ensure the portal meets the needs of patients, sites, and sponsors. With myMedidata, patients can virtually access all of their clinical trial needs through one web-based portal, removing the need for provisioned devices and improving clinical trial experiences.

More details at www.medidata.com.

-- BERNAMA